SQZ Insider Trading Activity and SEC Form 4 Filings
SQZ insider trading summary
No open-market insider purchases or sales of SQZ Biotechnologies Co (SQZ) have been reported on SEC Form 4 in the past 12 months.
Latest SQZ insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 15, 2022 | Richard Capasso | See Remarks | Sell | $4K (1,183 @ $3.33) |
| May 25, 2022 | Klavs F. Jensen | Director | Buy | $50K (14,326 @ $3.52) |
| Dec 13, 2021 | Amy W Schulman | Director | Buy | $20K (1,850 @ $10.94) |
| Dec 13, 2021 | Amy W Schulman | Director | Buy | $20K (1,850 @ $10.88) |
| Nov 3, 2020 | Pascal Minne | 10% Owner | Buy | $7.4M (465,000 @ $16.00) |
| Nov 3, 2020 | Temasek Holdings (Private) Ltd | 10% Owner | Buy | $10.0M (625,000 @ $16.00) |
| Nov 3, 2020 | Artal Group S.A. | 10% Owner | Buy | $7.4M (465,000 @ $16.00) |
| Nov 3, 2020 | International S.C.A. Artal | 10% Owner | Buy | $7.4M (465,000 @ $16.00) |
| Nov 3, 2020 | Invus Public Equities Advisors, LLC | 10% Owner | Buy | $7.4M (465,000 @ $16.00) |
| Nov 3, 2020 | Artal International Management S.A. | 10% Owner | Buy | $7.4M (465,000 @ $16.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.